Endocan alters nitric oxide production in endothelial cells by targeting AKT/eNOS and NFkB/iNOS signaling

Kumar, Sarwareddy Kartik; Mani, Krishna Priya

doi:10.1016/j.niox.2021.09.006

Cited by 24 publications

(15 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Endocan was reportedly involved in endothelial dysfunction in many pathological conditions including sarcoidosis [ 25 ], preeclampsia [ 26 ], and silent brain infarction [ 27 ]. Endocan probably exerts its effects on the vascular endothelium through alteration of nitric oxide secretion by activation of AKT/eNOS and NF- κ B/iNOS pathways [ 28 ].…”

Section: Discussionmentioning

confidence: 99%

Serum Endocan Levels and Subclinical Atherosclerosis in Patients with Chronic Kidney and End-Stage Renal Diseases

El-Senosy

Aziz

Kasim

et al. 2022

International Journal of Clinical Practice

View full text Add to dashboard Cite

Background and Aim. Chronic kidney disease (CKD) and its final stage: end-stage renal disease (ESRD), are common clinical conditions. Endocan is a human endothelial cell-specific molecule produced by endothelial cells. Its production is related to activation of endothelium and angiogenesis. In this study, we assessed the relation between serum endocan levels and subclinical atherosclerosis (SCA) in CKD and hemodialysis (HD) patients. Subjects and Methods. The present case control study enrolled 30 patients on regular HD for at least 6 months, 30 patients with CKD, and 30 age and sex-matched healthy controls. All participants were subjected to careful history taking and thorough clinical examination. Laboratory investigations included complete blood count, kidney functions, and serum cholesterol, triglycerides, calcium, phosphorus, albumin, PTH, hsCRP, and endocan levels. Results. HD and CKD groups had significantly higher endocan levels when compared with control group (median (IQR): 519.0 (202.3–742.0) versus 409.0 (245.3–505.3) and 273.0 (168.0–395.5) ng/L, respectively). Also, HD patients had significantly higher endocan levels when compared with CKD levels. HD patients had significantly higher carotid intima-media thickness (CIMT) when compared with CKD patients (median (IQR): 0.80 (0.80–0.90) versus 0.75 (0.73–0.75) mm, p < 0.001 ). HD patients had significantly higher frequency of SCA when compared with CKD patients (46.7% versus 13.3%, p = 0.005 ). Patients with SCA had significantly higher hsCRP (median (IQR): 36.5 (26.8–43.5) versus 24.0 (15.8–29.0) mg/dl) and endocan levels (697.0 (528.3–974.8) versus 222.5 (158.8–565.8) ng/L) when compared with patients without SCA. ROC curve analysis of endocan for identification of SCA in HD patients showed that at a cutoff of 380.5 ng/L, endocan has an AUC of 0.862 with a sensitivity and specificity of 92.9% and 68.7%, respectively. Conclusions. Serum endocan levels are related to SCA in HD patients. In addition, it is associated with the hyperinflammatory state in those patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Serum Endocan Levels and Subclinical Atherosclerosis in Patients with Chronic Kidney and End-Stage Renal Diseases

El-Senosy

Aziz

Kasim

et al. 2022

International Journal of Clinical Practice

View full text Add to dashboard Cite

show abstract

“…ESM1 is involved in the progression of multiple cancers, including proliferation, migration, invasion, drug resistance, angiogenesis, and apoptosis escape 13 , 18 , 19 . ESM1 could also regulate these molecular signaling pathways in cancer development and progression, such as the AKT/NF-kappaB/Cyclin D1 pathway 20 , Wnt/β-catenin pathway 18 , DLL4-Notch pathway 21 , AKT/eNOS 22 and NFkB/iNOS signaling 22 . To further elucidate the role of ESM1 in the development and progression of OC, we preliminarily explored its biological role in OC.…”

Section: Introductionmentioning

confidence: 99%

Validation of ESM1 Related to Ovarian Cancer and the Biological Function and Prognostic Significance

Li¹,

Zeng²,

Guan³

et al. 2023

Int. J. Biol. Sci.

View full text Add to dashboard Cite

Background: Ovarian cancer (OC), a serious gynecological malignant disease, remains an enormous challenge in early diagnosis and medical treatment. Based on the GEO and TCGA databases in R language, endothelial cell-specific molecule 1 (ESM1) was confirmed separately with the bioinformatic analysis tool. ESM1 has been demonstrated to be upregulated in multiple cancer types, but the oncogenic mechanism by which ESM1 promotes OC is still largely unknown. Methods: In this study, we used WGCNA and random survival forest variable screening to filter out ESM1 in OC differentially expressed genes (DEGs). Next, we confirmed the mRNA and protein levels of ESM1 in OC samples via PCR and IHC. The correlation between the ESM1 level and clinical data of OC patients was further confirmed, including FIGO stage, lymph node metastasis, and recurrence. The role of ESM1 in OC development was explored by several functional experiments in vivo and in vitro. Then, the molecular mechanisms of ESM1 were further elucidated by bioinformatic end experimental analysis. Results: ESM1 was significantly upregulated in OC and was positively correlated with PFS but negatively correlated with OS. ESM1 knockdown inhibited cell proliferation, apoptosis escape, the cell cycle, angiogenesis, migration and invasion in multiple experiments. Moreover, GSVA found that ESM1 was associated with the Akt pathway, and our results supported this prediction. Conclusion: ESM1 was closely correlated with OC development and progression, and it could be considered a novel biomarker and therapeutic target for OC patients.

show abstract

“… 23 Moreover, elevated endocan levels are associated with augmented oxidative stress. 24 In addition, endocan is known to promote proinflammatory mediators in the context of cardiovascular diseases. 25 …”

Section: Discussionmentioning

confidence: 99%

Serum Endocan Levels and Subclinical Atherosclerosis in Behçet’s Syndrome

Nassef¹,

Elabd²,

nagger³

et al. 2022

IJGM

View full text Add to dashboard Cite

Background and Aim Behçet disease (BD) is a rare chronic relapsing-remitting inflammatory systemic vasculitis. BD patients were reported to have marked acceleration of subclinical atherosclerosis (SCA). Endocan is a soluble proteoglycan mainly secreted by the activated endothelium. The present study aimed to assess the relation between serum endocan levels and SCA in BD patients. Subjects and Methods The study included 40 adult BD patients in addition to twenty age- and sex-matched healthy controls. BD was diagnosed according to International Study Group criteria. Upon recruitment, all participants were subjected to careful history taking and thorough clinical examination. BD activity was assessed using Behçet Syndrome Activity Score. Measurement of serum endocan was performed using quantitative double-antibody sandwich ELISA kit. CIMT measurement was done using B-mode ultrasound. Results Comparison between patients and controls regarding serum endocan levels revealed significantly higher endocan levels in BD patients [median (IQR): 155.0 (69.3–610.0) versus 73.8 (51.9–94.6)]. Using ultrasound assessment, SCA was found in 14 BD patients (35.0%). Comparison between patients with SCA and patients without regarding the clinical and laboratory data revealed that the former group had significantly higher CRP [median (IQR): 36.5 (26.8–43.5) versus 21.0 (11.8–26.8) mg/dL, p < 0.001] and endocan [median (IQR): 622.0 (107.4–974.8) versus 104.5 (64.0–342.0) mg/dL, p = 0.004] levels. Logistic regression analysis recognized endocan [OR (95% CI): 1.0 (1.0–1.012), p0.035] levels as significant predictor of SCA in multivariate analysis. Conclusion The present study identified the clinical value of serum endocan levels as a possible early marker of vascular involvement in BD patients.

show abstract

Endocan alters nitric oxide production in endothelial cells by targeting AKT/eNOS and NFkB/iNOS signaling

Cited by 24 publications

References 30 publications

Serum Endocan Levels and Subclinical Atherosclerosis in Patients with Chronic Kidney and End-Stage Renal Diseases

Serum Endocan Levels and Subclinical Atherosclerosis in Patients with Chronic Kidney and End-Stage Renal Diseases

Validation of ESM1 Related to Ovarian Cancer and the Biological Function and Prognostic Significance

Serum Endocan Levels and Subclinical Atherosclerosis in Behçet’s Syndrome

Contact Info

Product

Resources

About